GLP-1 Alone Isn’t Enough: Why Wraparound Support Is the Missing Piece

GLP-1 receptor agonists have revolutionised what’s possible in weight management. As a clinical lead dietitian running specialist NHS weight management services at Oviva, I see patients losing more weight, faster, than almost any treatment we’ve had before. But the medication is only half the story, and the half we don’t talk about enough is what happens to the body and behaviour underneath it.

Rapid weight loss whilst on a GLP-1 isn’t just fat loss. Without an adequate intake of protein and some resistance activity, a meaningful proportion of that weight lost is lean muscle. For the average patient this is a problem for long-term metabolic health and functional strength. For an older patient, this could mean a decline in mobility and independence which is the opposite of what “healthy weight loss” should look like. Micronutrient intake often falls too, simply because appetite and food volume have dropped so sharply. None of this shows up on the scales, which is exactly why it gets missed.

Then you’ve got to consider what happens when treatment stops. Appetite tends to return back to baseline once the medication is withdrawn, but the eating habits, routines and coping strategies that would sustain a lower weight often haven’t been built yet because the drug did the work the behaviour change was supposed to do. Weight regain after stopping is common, and it isn’t a failure of willpower. It’s a predictable consequence of treating the pharmacology without treating the person.

This is the case for wraparound support to include dietetic input, behavioural strategies, and structured follow-up delivered alongside the medication, not as an afterthought once problems appear. Within our services at Oviva , patients get this as standard: nutritional assessment, symptom management, and coaching that continues for the full duration of treatment and into any transition off it. The point isn’t to slow the weight loss down. It’s to make sure what’s lost is fat, what’s gained is a sustainable pattern of eating, and what happens next, whether that’s continuing the medication, stepping down or stopping, is planned rather than left to chance.

Pharmacy teams are often the most frequent point of contact a patient has during GLP-1 treatment, particularly where prescriptions are collected monthly. That’s a real opportunity. A few things are genuinely useful to flag or ask about at the counter:

• Are they eating enough protein? Nausea and reduced appetite make this hard. Simple, practical supportions such as protein with every meal, or a fortified drink on the worst days, go a long way.

• Any red-flag side effects? Persistent vomiting, severe abdominal pain, or signs of dehydration warrant a referral back to the prescriber, not just reassurance.

• Do they have a plan for what happens after treatment ends? If a patient doesn’t know, that’s worth flagging back to whoever is managing their care.

• Are they also seeing a dietitian or structured programme? If not, and if it’s available to them, this is worth actively encouraging rather than assuming someone else has covered it.

None of this requires pharmacy staff to become weight management specialists. It requires recognising that a prescription is the start of a treatment pathway, not the whole of it, and knowing when to point a patient towards the support that sits around the medication.

GLP-1s are a genuinely powerful tool. Used well with the right nutrition, behaviour change and monitoring built in from day one, they can deliver weight loss that lasts. Used in isolation, they too often deliver a result that reverses as soon as the injections stop. The difference isn’t the drug, it’s what’s built around it.

I'll be unpacking what good wraparound support looks like at the Pharmacy Show in Birmingham this October, so come and find me there. If you're looking to refer patients into structured GLP-1 support now, get in touch with Oviva's team to find out what's available in your area https://oviva.com/uk/en/refer/

[Louise Bula, Clinical Lead Dietitian, Oviva. NHS Tier 3 weight management, digital health, GLP-1 pathway clinical governance.]